Neuroblastoma regression and immunity induced by transgenic expression of interleukin-12
- 1 May 1999
- journal article
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 34 (5) , 902-907
- https://doi.org/10.1016/s0022-3468(99)90395-0
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- IL-2 Adenovector-Transduced Autologous Tumor Cells Induce Antitumor Immune Responses in Patients With NeuroblastomaBlood, 1998
- Combined chemokine and cytokine gene transfer enhances antitumor immunityNature Medicine, 1996
- Construction of a Double Recombinant Adenovirus Vector Expressing a Heterodimeric Cytokine:In VitroandIn VivoProduction of Biologically Active Interleukin-12Human Gene Therapy, 1996
- Experimental and Clinical Studies of Cytokine Gene-Modified Tumor CellsHuman Gene Therapy, 1994
- Antitumor and antimetastatic activity of interleukin 12 against murine tumors.The Journal of Experimental Medicine, 1993
- Interleukin-12 Promotes the Proliferation and Cytolytic Maturation of Immune EffectorsJournal of Immunotherapy, 1993
- Gene therapy: adenovirus vectorsCurrent Opinion in Genetics & Development, 1993
- Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradicationBritish Journal of Cancer, 1993
- Immunotherapy: Neuroblastoma as a ModelPediatric Clinics of North America, 1991
- Do infants with stage IV-S neuroblastoma need treatment?Archives of Disease in Childhood, 1981